To include your compound in the COVID-19 Resource Center, submit it here.

Oral Relistor methylnaltrexone: Completed Phase III enrollment

Salix disclosed in its 2Q11 earnings that in July it completed enrollment of about 700 patients with chronic non-cancer pain

Read the full 207 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE